|
| 37812652 | Surface and Global Proteome Analyses Identify ENPP1 and Other Surface Proteins as Actionable Immunotherapeutic Targets in Ewing Sarcoma. | Clin Cancer Res | 2024 |
| 36162055 | Sensitization to Ionizing Radiation by MEK Inhibition Is Dependent on SNAI2 in Fusion-Negative Rhabdomyosarcoma. | Mol Cancer Ther | 2023 |
| 37915590 | Comprehensive characterization of patient-derived xenograft models of pediatric leukemia. | iScience | 2023 |
| 37990009 | Genomic profiling of subcutaneous patient-derived xenografts reveals immune constraints on tumor evolution in childhood solid cancer. | Nat Commun | 2023 |
| 37243594 | EWSR1 maintains centromere identity. | Cell Rep | 2023 |
| 37359725 | DepLink: an R Shiny app to systematically link genetic and pharmacologic dependencies of cancer. | Bioinform Adv | 2023 |
| 36696581 | Redundant Signaling as the Predominant Mechanism for Resistance to Antibodies Targeting the Type-I Insulin-Like Growth Factor Receptor in Cells Derived from Childhood Sarcoma. | Mol Cancer Ther | 2023 |
| 36773293 | Nitric oxide suppression by secreted frizzled-related protein 2 drives retinoblastoma. | Cell Rep | 2023 |
| 36603130 | Sequential Targeting of Retinoblastoma and DNA Synthesis Pathways Is a Therapeutic Strategy for Sarcomas That Can Be Monitored in Real Time. | Cancer Res | 2023 |
| 36250964 | Evaluation of the pan-class I phosphoinositide 3-kinase (PI3K) inhibitor copanlisib in the Pediatric Preclinical Testing Consortium in vivo models of osteosarcoma. | Pediatr Blood Cancer | 2023 |
| 34737198 | Vertical Inhibition of the RAF-MEK-ERK Cascade Induces Myogenic Differentiation, Apoptosis, and Tumor Regression in <i>H/NRAS<sup>Q61X</sup></i> Mutant Rhabdomyosarcoma. | Mol Cancer Ther | 2022 |
| 35797217 | Regulation of TORC1 by MAPK Signaling Determines Sensitivity and Acquired Resistance to Trametinib in Pediatric BRAFV600E Brain Tumor Models. | Clin Cancer Res | 2022 |
| 35450020 | Approaches to identifying drug resistance mechanisms to clinically relevant treatments in childhood rhabdomyosarcoma. | Cancer Drug Resist | 2022 |
| 35657346 | Trastuzumab Deruxtecan, Antibody-Drug Conjugate Targeting HER2, Is Effective in Pediatric Malignancies: A Report by the Pediatric Preclinical Testing Consortium. | Mol Cancer Ther | 2022 |
| 36433963 | Genomic disparities between cancers in adolescent and young adults and in older adults. | Nat Commun | 2022 |
| 35129140 | Extrarenal Anaplastic Wilms Tumor: A Case Report With Genomic Analysis and Tumor Models. | J Pediatr Hematol Oncol | 2022 |
| 35312779 | Comprehensive Surfaceome Profiling to Identify and Validate Novel Cell-Surface Targets in Osteosarcoma. | Mol Cancer Ther | 2022 |
| 34997546 | Single-cell RNA profiling identifies diverse cellular responses to EWSR1/FLI1 downregulation in Ewing sarcoma cells. | Cell Oncol (Dordr) | 2022 |
| 35303054 | M6A RNA Methylation Regulates Histone Ubiquitination to Support Cancer Growth and Progression. | Cancer Res | 2022 |
| 35017650 | Splice-switching of the insulin receptor pre-mRNA alleviates tumorigenic hallmarks in rhabdomyosarcoma. | NPJ Precis Oncol | 2022 |
| 32810235 | PCAT: an integrated portal for genomic and preclinical testing data of pediatric cancer patient-derived xenograft models. | Nucleic Acids Res | 2021 |
| 33619171 | The B7-H3-Targeting Antibody-Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models. | Clin Cancer Res | 2021 |
| 33564073 | MNK1 and MNK2 enforce expression of E2F1, FOXM1, and WEE1 to drive soft tissue sarcoma. | Oncogene | 2021 |
| 33691584 | Regulation of DNA duplication by the mTOR signaling pathway. | Cell Cycle | 2021 |
| 33916592 | Developing New Agents for Treatment of Childhood Cancer: Challenges and Opportunities for Preclinical Testing. | J Clin Med | 2021 |
| 33915882 | Prioritization of Novel Agents for Patients with Rhabdomyosarcoma: A Report from the Children's Oncology Group (COG) New Agents for Rhabdomyosarcoma Task Force. | J Clin Med | 2021 |
| 35098099 | PEGylated talazoparib enhances therapeutic window of its combination with temozolomide in Ewing sarcoma. | iScience | 2021 |
| 34944795 | Altertoxin II, a Highly Effective and Specific Compound against Ewing Sarcoma. | Cancers (Basel) | 2021 |
| 34462275 | SNAI2-Mediated Repression of <i>BIM</i> Protects Rhabdomyosarcoma from Ionizing Radiation. | Cancer Res | 2021 |
| 34453478 | In vivo evaluation of the lysine-specific demethylase (KDM1A/LSD1) inhibitor SP-2577 (Seclidemstat) against pediatric sarcoma preclinical models: A report from the Pediatric Preclinical Testing Consortium (PPTC). | Pediatr Blood Cancer | 2021 |
| 34417181 | Predicting and characterizing a cancer dependency map of tumors with deep learning. | Sci Adv | 2021 |
| 34345820 | The effects of palbociclib in combination with radiation in preclinical models of aggressive meningioma. | Neurooncol Adv | 2021 |
| 34205996 | Dihydroartemisinin Inhibits mTORC1 Signaling by Activating the AMPK Pathway in Rhabdomyosarcoma Tumor Cells. | Cells | 2021 |
| 34233189 | NELL2-cdc42 signaling regulates BAF complexes and Ewing sarcoma cell growth. | Cell Rep | 2021 |
| 34137164 | Charting a path for prioritization of novel agents for clinical trials in osteosarcoma: A report from the Children's Oncology Group New Agents for Osteosarcoma Task Force. | Pediatr Blood Cancer | 2021 |
| 34108262 | International Consensus on Minimum Preclinical Testing Requirements for the Development of Innovative Therapies For Children and Adolescents with Cancer. | Mol Cancer Ther | 2021 |
| 33089597 | In vivo evaluation of the EZH2 inhibitor (EPZ011989) alone or in combination with standard of care cytotoxic agents against pediatric malignant rhabdoid tumor preclinical models-A report from the Pediatric Preclinical Testing Consortium. | Pediatr Blood Cancer | 2021 |
| 33420019 | Interaction between SNAI2 and MYOD enhances oncogenesis and suppresses differentiation in Fusion Negative Rhabdomyosarcoma. | Nat Commun | 2021 |
| 33323380 | A Very Long-Acting PARP Inhibitor Suppresses Cancer Cell Growth in DNA Repair-Deficient Tumor Models. | Cancer Res | 2021 |
| 32827353 | Radiation therapy and molecular-targeted agents in preclinical testing for immunotherapy, brain tumors, and sarcomas: Opportunities and challenges. | Pediatr Blood Cancer | 2021 |
| 31621900 | GD2-directed CAR-T cells in combination with HGF-targeted neutralizing antibody (AMG102) prevent primary tumor growth and metastasis in Ewing sarcoma. | Int J Cancer | 2020 |
| 32082485 | Tumor secreted ANGPTL2 facilitates recruitment of neutrophils to the lung to promote lung pre-metastatic niche formation and targeting ANGPTL2 signaling affects metastatic disease. | Oncotarget | 2020 |
| 31927611 | Prospective use of the single-mouse experimental design for the evaluation of PLX038A. | Cancer Chemother Pharmacol | 2020 |
| 31975571 | Preclinical evaluation of the combination of AZD1775 and irinotecan against selected pediatric solid tumors: A Pediatric Preclinical Testing Consortium report. | Pediatr Blood Cancer | 2020 |
| 33147457 | GDF6-CD99 Signaling Regulates Src and Ewing Sarcoma Growth. | Cell Rep | 2020 |
| 32706456 | Dose-response effect of eribulin in preclinical models of osteosarcoma by the pediatric preclinical testing consortium. | Pediatr Blood Cancer | 2020 |
| 32676162 | Development and characterization of the novel human osteosarcoma cell line COS-33 with sustained activation of the mTOR pathway. | Oncotarget | 2020 |
| 32184294 | Evaluation of Eribulin Combined with Irinotecan for Treatment of Pediatric Cancer Xenografts. | Clin Cancer Res | 2020 |
| 32333633 | Evaluation of VTP-50469, a menin-MLL1 inhibitor, against Ewing sarcoma xenograft models by the pediatric preclinical testing consortium. | Pediatr Blood Cancer | 2020 |
| 32207565 | Initial in vivo testing of a multitarget kinase inhibitor, regorafenib, by the Pediatric Preclinical Testing Consortium. | Pediatr Blood Cancer | 2020 |